

CLAIM AMENDMENTS

1. (currently amended): A drug carrier system comprising a plurality of colloidal particles said particles having a core and a shell and comprising a copolymer consisting of hydrophilic blocks,

which copolymer comprises at least one A block and at least one B block different from the at least one A block,

wherein the at least one A block consists of a hydrophilic polymer unit of a first set of monomers and the at least one B block consists of a hydrophilic polymer unit of a second set of monomers,

wherein the first set of monomers and the second set of monomers are selected so that polymers consisting only of monomers of the first set and polymers consisting only of monomers of the second set are capable of forming an aqueous two-phase system, and

wherein the A blocks in particles form the core and the B blocks in the particles form the shell.

2. (previously presented): The drug carrier system of claim 1, wherein said particles comprise a micellar structure.

3. (previously presented): The drug carrier system of claim 1, having intermolecular crosslinks between at least some of the A blocks in the same particle.

4. (previously presented): The drug carrier system of claim 1, having intermolecular crosslinks between at least some of the B blocks in the same particle.

5. (previously presented): The drug carrier system of claim 1, further comprising a polymer consisting of monomers of the first set.

6. (previously presented): The drug carrier system of claim 5, having intermolecular crosslinks between at least some of the A blocks in the copolymer and at least some of the chains of the polymer consisting of monomers of the first set in the same particle.

7. (previously presented): The drug carrier system according to claim 1, wherein the A block has a biodegradable backbone.

8. (previously presented): The drug carrier system of claim 3, having biodegradable spacers between block A and at least some of the intermolecular crosslinks.

9. (original): The drug carrier system of claim 8, wherein the biodegradable spacers comprise a hydrolysable ester bond, a hydrolysable amide bond, or a hydrolysable carbonate bond.

10. (previously presented): The drug carrier system of claim 1, wherein the A block consists of a polymer unit of saccharides or derivatives thereof.

11. (original): The drug carrier system according to claim 10, wherein the saccharide is a dextran, optionally modified with an acrylic, a methacrylic or a hydroxyethylmethacrylic group.

12. (previously presented): The drug carrier system of claim 1, wherein the B block consists of a polymer unit of ethylene glycols.

13. (previously presented): The drug carrier system of claim 1, wherein the colloidal particles are substantially insoluble in an aqueous liquid at physiological conditions.

14. (previously presented): The drug carrier system of claim 1, wherein the colloidal particles have a mean particle size of between 5 nm and 50 μm .

15. (previously presented): The drug carrier system of claim 1, further comprising an active ingredient and preferably a pharmaceutically active ingredient.

16. (previously presented): A pharmaceutical composition comprising the colloidal drug carrier system of claim 1.

17-36. (canceled)

37. (previously presented): The drug carrier system of claim 6, having biodegradable spacers between block A and at least some of the intermolecular crosslinks.

38. (canceled)